Treatment with exogenous TGF-β conferred insensitivity to trastuzumab in HER2-positive breast cancer cell lines, through up-regulating the expression of EMT and cancer stem cell (CSC) markers (Chihara et al., 2017). This evidence concerns the gene ERBB2 and breast carcinoma.